Eli Lilly's Weight-Loss Drug Demand Is Nearly Limitless. Here's What Comes Next for the $1 Trillion Drugmaker

Eli Lilly’s weight-loss pipeline is translating directly into financial momentum after the company posted a blowout second-quarter earnings report on Wednesday. Shares rose 4.4% as the drugmaker remained the only pharma company trading above a $1 trillion market cap. Earnings came in above expectations at $3.28 per share, while revenue jumped 48% year over year to $22.97 billion, driven mainly by Mounjaro and Zepbound volume. U.S. Mounjaro sales climbed 91% to $9.9 billion; Zepbound rose 46% to $4.9 billion. International Mounjaro revenue grew 172%, helped by its addition to China’s National Reimbursement Drug List. Management raised full-year revenue guidance to $85.0–$87.0 billion and pointed to a planned Q1 2027 BLA for retatrutide.